Interferon β (IFNβ) represents a standard treatment for relapsing-remitting MS and exogenous administration of IFNβ exhibits protective effects in experimentally induced CNS autoimmunity. Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.